N-methyl-1-phenylpropan-2-amine

URI: https://gptkb.org/entity/N-methyl-1-phenylpropan-2-amine
GPTKB entity
Statements (42)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
amphetamine
gptkbp:alternativeName amphetamine
gptkbp:ATCCode N06BA03
gptkbp:boilingPoint 215 °C
gptkbp:CASNumber 537-46-2
gptkbp:drugClass stimulant
anorectic
gptkbp:eliminationHalfLife 9–12 hours
gptkbp:has_discovered_by gptkb:Nagai_Nagayoshi
gptkbp:has_discovered_year 1893
gptkbp:has_excretion urine
gptkbp:has_metabolism liver
gptkbp:has_parent_compound amphetamine
gptkbp:hasInChIKey KWTSXDURSIMDCE-UHFFFAOYSA-N
gptkbp:hasMolecularFormula C10H15N
gptkbp:hasSMILES CC(CC1=CC=CC=C1)NC
gptkbp:hasUNII 44RAL3456C
https://www.w3.org/2000/01/rdf-schema#label N-methyl-1-phenylpropan-2-amine
gptkbp:IUPACName gptkb:N-methyl-1-phenylpropan-2-amine
gptkbp:legalStatus gptkb:Narcotic_(Japan)
gptkb:Schedule_8_(Australia)
Class A drug (UK)
Schedule II controlled substance (US)
Schedule I controlled substance (Canada)
gptkbp:medicalUse treatment of ADHD
treatment of obesity
gptkbp:meltingPoint 170 °C (hydrochloride salt)
gptkbp:PubChem_CID 10367
10836
gptkbp:relatedTo gptkb:ephedrine
gptkb:MDMA
gptkb:pseudoephedrine
gptkbp:routeOfAdministration oral
intravenous
smoked
insufflated
gptkbp:sideEffect insomnia
addiction potential
increased blood pressure
gptkbp:bfsParent gptkb:amphetamine
gptkbp:bfsLayer 6